Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Boswellic acid, a major active component of Boswellia serrata (also known as Indian frankincense), has been investigated for its anti-inflammatory properties, including potential benefits in inflammatory bowel diseases such as Crohn's disease. The rationale for its use is based on its inhibition of 5-lipoxygenase, an enzyme involved in leukotriene synthesis and inflammatory processes. Several small clinical trials and preclinical studies have assessed Boswellia extracts for their activity in ulcerative colitis and Crohn's disease. Notably, a randomized, double-blind, placebo-controlled pilot study published in the European Journal of Medical Research (2001) showed that Boswellia extract was as effective as mesalazine in maintaining remission in patients with Crohn’s disease, although the sample size was limited. Additional studies have shown an improvement in symptoms and inflammatory markers, but the evidence is inconsistent and generally limited by small cohorts and methodological flaws. Systematic reviews conclude that while there is some promising evidence for Boswellic acid’s anti-inflammatory effects in IBD, the quality and quantity of data for Crohn’s disease specifically is low, and larger, high-quality trials are needed. Therefore, while some scientific evidence exists to justify its use, it is not strong or definitive, and Boswellic acid should not be considered a standard treatment for Crohn’s disease at this time.

More about Boswellic Acid
More about Crohn's Disease

Other ingredients used for Crohn's Disease

Other health conditions supported by Boswellic Acid

Products containing Boswellic Acid